B.Riley/FBR Starts Actinium Pharma (ATNM) at Buy Citing Novel Approach To Treating Certain Blood Cancers
Tweet Send to a Friend
B.Riley/FBR initiates coverage on Actinium Pharma (NYSE: ATNM) with a Buy rating and a price target of $2.75.Analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
